Compare the Therapeutic Effect Treated With Tamsulosin and Progesterone After ESWL( Extra Corporeal Shock Wave Lithotripsy) in Urinary Calculus

NCT ID: NCT01010048

Last Updated: 2009-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the stone clearance rate treated with different drugs after ESWL in urinary calculus,These drugs are often used in urinary calculus,such as progesterone,tamsulosin,propantheline Bromide and nifedipine.In these study the investigators want to investigate different effect of these drugs use to treat urinary calculus after ESWL.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is 4 groups in these investigation, group1 urinary calculus treated with ESWL only ,group2 urinary calculus treated with ESWL and tamsulosin,group3 urinary calculus treated with ESWL and progesterone,group4 urinary calculus treated with ESWL ,propantheline Bromide and nifedipine.We want to investigate which one is better or not in urinary calculus treated with ESWL .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Calculus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

progesterone,tamsulosin,propantheline Bromide and nifedipine

different effect of these drugs use to treat urinary calculus after ESWL

Group Type EXPERIMENTAL

progesterone,tamsulosin,propantheline Bromide and nifedipine

Intervention Type DRUG

clearance rate of stone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

progesterone,tamsulosin,propantheline Bromide and nifedipine

clearance rate of stone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* From 18 years old to 68 years old,
* urinary calculus could be treated by ESWL,
* the calculus size is from 4-25mm

Exclusion Criteria

* Less than 18 years old or more than 68 years old,
* the calculus size is from Less than4 or larger than 25mm
Minimum Eligible Age

18 Years

Maximum Eligible Age

68 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chongqing Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

The First Affiliated Hospital ,Chongqing Medical University

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

xiaohou wu, doctor

Role: STUDY_CHAIR

First Affiliated Hospital of Chongqing Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The First Affiliated Hospital, ChongQing medical University

Chongqing, Chongqing Municipality, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yunfeng He, Doctor

Role: CONTACT

86-23-89011121

Xiaohou Wu, Doctor

Role: CONTACT

86-23-89011122

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yunfeng He, Doctor

Role: primary

86-23-89011121

Xiaohou Wu, Doctor

Role: backup

86-23-89011122

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CQMU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Silodosin vs Tamsulosin as MET
NCT05570084 UNKNOWN PHASE3